Eli Lilly (LLY) Depreciation and Depletion (2014 - 2015)
Eli Lilly (LLY) posted Depreciation and Depletion of $216.6 million for Q2 2015, up 1197.01% quarter-over-quarter from $16.7 million in Q1 2015, and little changed year-on-year from $216.3 million in Q2 2014.
Eli Lilly (LLY) Depreciation and Depletion (2014 - 2015) Analysis & Trends
Eli Lilly (LLY) has reported Depreciation and Depletion for 2 consecutive years, with $216.6 million the latest figure, recorded in Q2 2015.
- Depreciation and Depletion for Q2 2015 came in at $216.6 million, changed 0.14% year-over-year; the trailing twelve-month figure through Jun 2015 was $463.2 million (changed N/A YoY), and the FY2025 annual result was $1.3 billion, up 24.2% from the prior year.
- Depreciation and Depletion was $216.6 million for Q2 2015 at Eli Lilly, up from $16.7 million in the prior quarter.
- Over five years, Depreciation and Depletion peaked at $216.6 million in Q2 2015 and troughed at $13.6 million in Q1 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 188.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 581.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 93.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 67.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2015 | 216.60 Mn |
| Jun 30, 2015 | 216.60 Mn |
| Mar 31, 2015 | 16.70 Mn |
| Mar 31, 2015 | 16.70 Mn |
| Jun 30, 2014 | 216.30 Mn |
| Jun 30, 2014 | 216.30 Mn |
| Mar 31, 2014 | 13.60 Mn |
| Mar 31, 2014 | 13.60 Mn |